Introduction: Accumulating evidence suggests that cyclooxygenase-2 (COX-2) is involved in growth, progression and metastasis of human osteosarcomas (OSs) and that its expression correlates with a poorer prognosis. The aim of this report was to study the expression of COX-2 in healthy, reactive, and neoplastic canine bone and to investigate the events downstream to COX-2 that lead to PGE2 production by the evaluation of mPGES-1 and EP2 receptor expression. Materials and Methods: COX-2, mPGES-1 and EP2 receptor expression were assessed by immunohistochemistry in 12 samples of normal bone, 14 reactive bones and 27 appendicular OSs. The streptavidin-peroxidase method was used. The results were quantified according to previously described scores. Results: In healthy tissues no immunoreactivity to COX-2, mPGES-1 and EP2 receptor was observed. Fifty percent of reactive bone samples scored positive for COX-2 and 57% for mPGES-1 and EP2 receptor, although with a weak labelling intensity. Ninety-three percent of OSs expressed COX-2; mPGES-1 was expressed in 85% and EP2 receptor in 89% of tumours.
IMMUNOHISTOCHEMICAL EXPRESSION OF COX-2, MPGES-1 AND EP2 RECEPTOR IN HEALTHY AND REACTIVE CANINE BONE AND IN OSTEOSARCOMAS
VIGNOLI, Massimo;
2012-01-01
Abstract
Introduction: Accumulating evidence suggests that cyclooxygenase-2 (COX-2) is involved in growth, progression and metastasis of human osteosarcomas (OSs) and that its expression correlates with a poorer prognosis. The aim of this report was to study the expression of COX-2 in healthy, reactive, and neoplastic canine bone and to investigate the events downstream to COX-2 that lead to PGE2 production by the evaluation of mPGES-1 and EP2 receptor expression. Materials and Methods: COX-2, mPGES-1 and EP2 receptor expression were assessed by immunohistochemistry in 12 samples of normal bone, 14 reactive bones and 27 appendicular OSs. The streptavidin-peroxidase method was used. The results were quantified according to previously described scores. Results: In healthy tissues no immunoreactivity to COX-2, mPGES-1 and EP2 receptor was observed. Fifty percent of reactive bone samples scored positive for COX-2 and 57% for mPGES-1 and EP2 receptor, although with a weak labelling intensity. Ninety-three percent of OSs expressed COX-2; mPGES-1 was expressed in 85% and EP2 receptor in 89% of tumours.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
